Published by Josh White on 12th December 2024
(Sharecast News) - Hutchmed China announced on Thursday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to the combination of 'Orpathys', or savolitinib, and 'Tagrisso', or osimertinib.